Cargando…

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis

BACKGROUND: Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor used as monotherapy in early Parkinson's disease and as an adjunct therapy to levodopa in Parkinson's disease with motor fluctuations. OBJECTIVES: This meta-analysis aimed to provide updated evidence on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kano, Osamu, Tsuda, Hiroshi, Hayashi, Ayako, Arai, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448622/ https://www.ncbi.nlm.nih.gov/pubmed/36081594 http://dx.doi.org/10.1155/2022/4216452

Ejemplares similares

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Adjunctive therapy in Parkinson’s disease: the role of rasagiline
por: Gaines, Kathryn D, et al.
Publicado: (2012)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

The role of rasagiline in the treatment of Parkinson’s disease
por: Leegwater-Kim, Julie, et al.
Publicado: (2010)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review
por: Sanchez Alonso, Pilar, et al.
Publicado: (2023)

Long-term treatment of Parkinson’s disease with levodopa and other adjunctive drugs
por: Mizuno, Yoshikuni, et al.
Publicado: (2017)

Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China
por: Zhang, Zhenxin, et al.
Publicado: (2018)

Effects of rasagiline combined with levodopa and benserazide hydrochloride on motor function and homocysteine and IGF-1 levels in elderly patients with Parkinson’s disease
por: Yang, Yifan, et al.
Publicado: (2023)

Levodopa-Responsive Benign Tremulous Parkinsonism
por: Kano, Osamu, et al.
Publicado: (2013)

Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson’s disease - network meta-analysis
por: Sako, Wataru, et al.
Publicado: (2023)

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson’s Disease: Review of Literature
por: Pistacchi, Michele, et al.
Publicado: (2013)

Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
por: Malaty, Irene A, et al.
Publicado: (2009)

From a Parkinson's disease expert: Rasagiline and the Future of Therapy
por: Lakhan, Shaheen E
Publicado: (2007)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation
por: Yi, Zhan-Miao, et al.
Publicado: (2018)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
por: Annus, Ádám, et al.
Publicado: (2017)

Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
por: Lecht, Shimon, et al.
Publicado: (2007)

Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
por: Wang, Libo, et al.
Publicado: (2018)

Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study
por: Hatano, Taku, et al.
Publicado: (2022)

Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: A systematic review and meta-analysis
por: Wang, Yan, et al.
Publicado: (2021)

Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease
por: Petit, Géraldine H., et al.
Publicado: (2013)

Rasagiline for sleep disorders in patients with Parkinson’s disease: a prospective observational study
por: Schettino, Carla, et al.
Publicado: (2016)

Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study
por: Peretz, Chava, et al.
Publicado: (2016)

Rasagiline, sleep quality and well-being in Parkinson’s disease: a pilot study
por: Mutti, Carlotta, et al.
Publicado: (2022)

Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022)

Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study
por: Murata, Miho, et al.
Publicado: (2018)

Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
por: Finberg, John P.M.
Publicado: (2010)

Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson’s disease
por: Jiang, Ying, et al.
Publicado: (2017)

Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017)

Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson’s disease
por: Oka, Hisayoshi, et al.
Publicado: (2021)

Curcumin modulation of L-dopa and rasagiline-induced neuroprotection in rotenone model of Parkinson’s disease
por: El-Shamarka, Marwa El-Sayed, et al.
Publicado: (2023)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice
por: Zheng, Cheng-you, et al.
Publicado: (2016)

Levodopa treatment patterns in Parkinson’s disease: A retrospective chart review
por: Navaratnam, Prakash, et al.
Publicado: (2022)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review
por: Tsunemi, Taiji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_skqte4ihh646edhdhnshbmm594